ly2109761

LY2109761 is an **orally active, small-molecule dual inhibitor** of the **transforming growth factor beta type I and type II receptors (TGF-βRI and TGF-βRII) serine/threonine kinases**, developed by Eli Lilly. It has demonstrated preclinical efficacy in inhibiting TGF-β-mediated signaling pathways, particularly by blocking phosphorylation of Smad proteins, leading to reduced tumor cell proliferation, migration, invasion, metastasis (notably in pancreatic and hepatocellular carcinoma models), and radiation-induced fibrosis. The compound has been investigated as a potential **antineoplastic and antifibrotic agent**, with studies indicating action both on tumor cells and the tumor microenvironment, including modulation of immune responses and suppression of proinflammatory and proangiogenic signals[1][2][3].